Show results for
Refine by
Preclinical Data Suppliers Serving Ohio
39 companies found
based inLa Jolla, CALIFORNIA (USA)
Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
based inSanta Clara, CALIFORNIA (USA)
Shape Memory Medical is a California-based, global medical device company focused on innovative therapeutic solutions using shape memory polymer technology Shape Memory Medical is the only company using the science of smart polymer to address ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the ...
based inNorwich, UNITED KINGDOM
We are a passionate and skilled drug discovery and development biotech team developing an innovative new class of oligonucleotide antimicrobial agents. Procarta is currently working on lead optimisation for its first product, a narrow-spectrum agent ...
Proprietary nanoparticles deliver an oligonucleotide inside the bacterial pathogen. The oligonucleotide acts as a Transcription Factor Decoy (TFD): it contains the binding site of a transcription factor that controls a large set of genes required ...
based inLawrence, KANSAS (USA)
Pinnacle specializes in providing reliable, robust turn-key solutions for neurophysiology research. We are always striving to bring you new and innovative tools that simplify measurement, reduce cost, and enable new discoveries. Pinnacle Technology ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
based inStockholm, SWEDEN
Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd and the oral regenerative and immunomodulatory therapeutic ...
based inSeattle, WASHINGTON (USA)
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged ...
AVM0703 Induces & Mobilizes Gamma Delta+ NKT-Cells. AVM0703 triggers the production and release of gamma delta+ Natural Killer T-cells (AVM-NKT). These supercharged immune cells have unique properties and appear rapidly in the blood following a ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
TILs are part of the body’s natural response to cancer:The cells of the immune system perform immunosurveillance while circulating throughout the bodyAs part of the normal immune response, TIL migrate to the tumor site through recognition of ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Generic peptide pharmaceuticals are products that replicate existing peptide drugs. These drugs are typically composed of amino acids linked by peptide bonds and are used to treat a variety of diseases, including cancer, diabetes, and immune ...
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin ...
based inCambridge, UNITED KINGDOM
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and ...
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure ...
based inSeattle, WASHINGTON (USA)
We are a pre-clinical-stage biotech company combining protein design and screening to create novel biologics for serious unmet medical needs. Using this approach, we are developing an early pipeline of innovative programs in multiple indications. ...
Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T ...
based inSeillans, FRANCE
RespInnovation SAS designs, develops and markets the RespIn 11 Bronchial Clearance System. A focused pulse bronchial clearance system based on high frequency chest wall oscillation (HFCWO) therapy for the treatment of many diseases with chronic ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Prostate cancer is the most common type of cancer (aside from skin) in American men with 13 out of every 100 being diagnosed with the disease during their lifetime.1,2Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is ...
based inMunich, GERMANY
Leaders in optoacoustic imaging through innovation and collaboration; Optoacoustic imaging is a very complex field, both from a technology and applications perspective. Components to master include lasers, optics, ultrasound detectors, electronics, ...